Improve recognizing emotions on medication
- Trial ID
- NCT06884722
- Official Title
- Social Perception and Dopaminergic Modulation in Patients With Parkinson's Disease: a Functional MRI Study (Park Social-E-Motion)
- Goal
- Improve recognizing emotions on medication
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Hospices Civils de Lyon
- Study Type
- INTERVENTIONAL
- Enrollment
- 83 participants
- Conditions
- Social Perception in Parkinson's Disease
- Interventions
- Behavioral task of social perception (stage 1), Functional magnetic resonance imaging: 3 Tesla magnetic resonance imaging (stage 2), Neurological and neuropsychological assessments, Neurological assessments of Parkinson's disease symptoms and caregiver burden
Plain-Language Summary
The goal is to understand how Parkinson's and dopamine treatment change the way people perceive social cues like faces and emotions, because those social and emotional difficulties can be common and distressing. Participants complete simple social perception tasks while researchers record brain activity with 3 Tesla fMRI, comparing responses in people on their usual dopaminergic medications, since those drugs boost brain dopamine and can alter emotional and social processing; the study also includes neurological, neuropsychological, and caregiver burden assessments. Looking for people aged 30 to 75 who have had Parkinson's for at least 3 years, are taking dopaminergic treatment, and do not have disabling cognitive impairment (MoCA 26 or higher); healthy volunteers are also recruited for the imaging part.
Locations
- Service de neurologie - troubles du mouvement et pathologies neuromusculaires, Hôpital neurologique Pierre Wertheimer/GHE, Bron, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Behavioral task of social perception (stage 1). The goal is to understand how Parkinson's and dopamine treatment change the way people perceive social cues like faces and emotions, because those social and emotional difficulties can be common and distressing. Participants complete simple social perception tasks while researchers record brain activity with 3 Tesla fMRI, comparing responses in people on their usual dopaminergic medications, since those drugs boost brain dopamine and can alter emotional and social processing; the study also includes neurological, neuropsychological, and caregiver burden assessments. Looking for people aged 30 to 75 who have had Parkinson's for at least 3 years, are taking dopaminergic treatment, and do not have disabling cognitive impairment (MoCA 26 or higher); healthy volunteers are also recruited for the imaging part.
- Who can participate?
- Participants must be between 30 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 9 months.